Citations

Clear

299 citation(s) found for "Solomon, G M".

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004
Wierda, William G. , Dorritie, Kathleen , Gauthier, Jordan , Nath, Rajneesh, Kipps, Thomas J. , Riedell, Peter A. , Eradat, Herbert A., Kharfan‐Dabaja, Mohamed A. , Shah, Nirav N. , Solomon, Scott R., Stephens, Deborah M., Ermann, Daniel A., Arnason, Jon , Deol, Abhinav , Feldman, Tatyana , Ghosh, Monalisa , Tuazon, Sherilyn A., Perna, Serena K., Ou, San-San, Ananthakrishnan, Revathi , Rane, Neha, Papp, Eniko, Ansari, Sahar , Thompson, Ethan G., Okal, Abood, Peiser, Leanne, Chen, Yizhe , Sengupta, Sanhita , Wang, Jixian , Wierda, William G. , Dorritie, Kathleen , Kenderian, Saad S. , Kharfan-Dabaja, Mohamed A , Shah, Nirav N , Deol, Abhinav , Ma, Shuo , Schuster, Stephen J , Gergis, Usama , Vose, Julie , Soumerai, Jacob D , Besien, Koen van , Chen, Yizhe , Sengupta, Sanhita , Ray, Pradipta Ranjan , Siddiqi, Tanya , Kipps, Thomas J , Riedell, Peter A , Nath, Rajneesh , Eradat, Herbert, Stephens, Deborah M. , Andreadis, Charalambos Babis , Ma, Shuo , Schuster, Stephen J. , Vose, Julie M. , Soumerai, Jacob D. , Tuazon, Sherilyn A. , Perna, Serena , Ou, San‐San , Papp, Eniko , Ansari, Sahar, Siddiqi, Tanya

Mayo Clinic

Blood Journal | July 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2026033565 | PMID 42520199 Get It

Patients in the liso-cel plus ibrutinib cohort of the phase 1/2, open-label TRANSCEND CLL 004 study had relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and received liso-cel (50×106 [dose level (DL)1] or 100×106 [DL2] chimeric antigen receptor-positive T cells) with concurrent ibrutinib from enrollment through 90 days after liso-cel infusion or longer per investigator discretion. Primary end point was complete response/remission (CR)/CR with incomplete marrow recovery (CRi) by investigator assessment. Among 56 patients who received ibrutinib plus liso-cel (DL1, n=5; DL2, n=51), median (range) age was 64.5 years (44‒77), 98% had high-risk cytogenetics, 55% had progression on Bruton tyrosine kinase inhibitor and venetoclax failure, and median (range) number of prior therapies was 5 (1‒13). Median (range) follow-up was 24.8 months (3.1‒51.8). At DL2, CR/CRi rate was 45% (95% confidence interval [CI], 31‒60) and overall response rate was 86% (95% CI, 74‒94). Median (95% CI) duration of response was not reached (NR; 28.7‒NR) for patients with CR/CRi and 41.4 months (23.3‒NR) for all responders. Median (95% CI) progression-free survival was 31.4 months (20.1‒NR). In DL1+DL2, most common grade ≥3 treatment-emergent adverse events (TEAE) were neutropenia (52%) and anemia (41%). Cytokine release syndrome was reported in 80% of patients (grade 3, 4%; no grade 4/5), and neurological events in 41% (grade 3/4, 11%; no grade 5). Ibrutinib-related TEAEs were reported in 68% of patients (grade 3/4, 43%; no grade 5). Liso-cel plus ibrutinib demonstrated notable efficacy in patients with relapsed/refractory CLL/SLL with predictable and manageable safety. Clinicaltrials.gov: NCT03331198; NCT03435796.
Advancing Prostate Cancer Survivorship Through Transatlantic Consortium Science: The iCCaRE Initiative
Odedina, Folakemi T. , Dronca, Roxana , Ashing, Kimlin , Kaninjing, Ernest , Rotimi, Solomon O. , Ngufor, Che , Merriweather, Arnold , Gordon, Vinessa , Asto-Flores, Emelina , Adeniji, Kayode, Agboola, Emmanuel, Aliche, Uju, Aliyu, Usman M., Ashing, Kimlin Tam, Asiedu, Gladys, Badejo, Paul, Johnson, Kim Barbel, Beckford, Patrick , Blocker, Renaldo, Bolajoko, Opeyemi, Bonner, Timethia J, Breland, Ivey, Caballero, Amanda , Carter, Rickey, Cattnell, Alex, COBRAN, Ewan, Colon-Otero, Gerardo, Copland, John A., Phd, Getachew Dagne, Campos, Opeyemi C. De, Doty, Melissa, Dronca, Roxana, Erefah, Ebenezer, Falzon, Kaila, Francis, Damian, Fudge, Michelle, Fullwood, Dottington , Gainer, Jeffery, Glaser-Boivin, Dee, Hill, Antony, Hinsom, Rakenya, Iweala, Emeka J., Kaninjing, Ernie, Kase, Adam, Knutsen, Keith, Lee, Daniel, Leyva, Sandra Casanova, Lindeman, Carolyn R., Mahin, Collisa, Maniaci, Michael, Hew, Trevanne Matthews, Hew, Trevanne R. Matthews, Melton, Jada K., Merriweather, Arnold, Mitchell, Luisa, Moore, Cassandra, Ngufor, Che, Nolan, Lucia, Odedina, Abimbola, Odedina, Folakemi, Oladoyinbo, Catherine, Olasehinde, Esther, Onyia, Abimbola F., Popoola, Ademoola, Rotimi, Solomon O., Scales, Tracie, Sledge, Hanna, Thompson-Reeves, Jade, Toye, Oluwaseyi, Duarte, Claudia Valles, Voorhis, Kaitlin Van, Waldon, Charles F., Walsh-Childers, Kim , Williams, Christopher, Willis, Floyd , Wimberly, Quincy , Yahaya, Ayinde, Yates, PhD Clayton, Yost, Kathleen, Young, Mary Ellen , Zou, Tingyu, Ashing, Kimlin Tam , Rotimi, Solomon , Odedina, Folakemi , Kaninjing, Ernest T , Ngufor, Che G , Aliche, Uju, Badejo, Paul, Blocker, Renaldo, Bolajoko, Opeyemi , Cattnell, Alex, Cobran, Ewan K. , Colon-Otero, Gerardo, Copland, John A., Francis, Damian, Fudge, Michelle , Gainer, Jeffery, Gokara, Mahesh , Hinsom, Rakenya, Iweala, Emeka J., Knutsen, Keith, Lee, Daniel, Lindeman, Carolyn R., McCall, John , Melton, Jada K., Mitchell, Luisa, Olasehinde, Esther, Popoola, Ademoola, Reynolds, Jordan , Scales, Tracie, Sledge, Hanna, Thompson-Reeves, Jade, Toye, Oluwaseyi, Duarte, Claudia Valles, Voorhis, Kaitlin Van, Waldon, Charles F., Williams, Christopher, Yost, Kathleen, Zou, Tingyu

Mayo Clinic

Cancer Research Communications | July 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/2767-9764.crc-26-0165 | PMID 42497456 Get It

Abstract Black/African American populations, globally, bear the greatest prostate cancer (CaP) burden compared to other racial/ethnic groups. Addressing CaP disparities in Black men is complex, requiring a patient-centered, community-centric and comprehensive approach. This study integrates iCCaRE Consortium findings and broader literature to address unmet needs in survivorship care. The iCCaRE Consortium implemented five complementary pilot studies using mixed-methods designs, including feasibility trials, qualitative research, and observational analyses across the United States and sub-Saharan Africa. Descriptive statistics, subgroup analyses, and qualitative thematic analyses were performed across these studies. Collectively, projects addressed multilevel determinants including social, behavioral, and biological drivers of disparities. Project 1 implemented a Virtual Reality Assistant (ViRA) across clinical and community settings, with ongoing evaluation in pragmatic trials. Project 2 showed strong patient preference for home-based cancer care. Project 3 enrolled demonstrated trends toward improved health-related quality of life. Project 4 identified key themes influencing survivorship experiences. Project 5 identified biological mechanisms linking stress, immune modulation, and symptom burden. The iCCaRE pilot projects demonstrate the feasibility and early impact of a consortium-based, transdisciplinary approach to addressing CaP disparities in Black men. These findings highlight the importance of integrating patient-centered interventions, community engagement, and biological insights to inform scalable strategies aimed at improving survivorship outcomes and advancing health equity. The iCCaRE Consortium demonstrates that a transatlantic, patient-centered, and multidisciplinary approach integrating social, clinical, and biological factors can generate scalable strategies to improve survivorship outcomes and advance equity in CaP care for Black men.
Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
A, Prera Vilaseca, Bilodeau, Philippe, Gakis, Georgios , Savransky, Andrea, Oliveira, Joao Mahler Ferreira, Nguyen, Linda, Hooshmand, Sam I., Satyanarayan, Sammita , Moseley, Carson E., Haley, Leah , Roy-Hewitson, Chantal, Marrodan, M, Casallas, Adriana, Manín, Analisa , Chen, H, Grzezulkowska, Aniela, Contentti, Edgar Carnero, Galleguillos, Lorna, Upchurch, Margaret, Jackson-Tarlton, Caitlin S. , Guo, Joanne Chu-Yueh, Fabian, Michelle, Caparó-Zamalloa, César, Paterno, R, Waubant, Emmanuelle, Boschetti, Laura Ordoñez, Correale, Jorge, Villa, Andrés M., Banwell, Brenda, Marignier, Romain, Pittock, Sean J., Greenberg, Benjamin , Bennett, Jeffrey L., Cho, Tracey, Clardy, Stacey, Solomon, Andrew J., Ja, Gelfand, Obeidat, Ahmed Z., Blackburn, Kyle, Tenembaum, Silvia , Chen, John J., Sotirchos, Elias S., Levy, Michael, Flanagan, Eoin P., Group, and The Americas MOGAD Treatment, Murillo, Fabian, Syc-Mazurzek, Stephanie B., Jiang, Mulan , Rezende, N, Wingerchuk, D M, Horsman, Susan E. , Bilodeau, Philippe‐Antoine , Bilodeau, Philippe A , Vilaseca, Andreu , Hooshmand, Sam , Moseley, Carson E. , Marrodán, Mariano , Vanegas, Adriana Casallas , Hoshina, Yoji , Contentti, Edgar Carnero , Galleguillos, Lorna , Virupakshaiah, Akash , Arrambide, Georgina , Caparó‐Zamalloa, César , Waubant, Emmanuelle L. , Ordóñez-Boschetti, Laura, Villa, Andres Maria , Marignier, Romain , Pittock, Sean J. , Bennett, Jeffrey L. , Cho, Tracey , Clardy, Stacey , Solomon, Andrew , Kister, Ilya , Zamvil, Scott S. , Gelfand, Jeffrey M. , Repovic, Pavle , Obeidat, Ahmed Zayed , Blackburn, Kyle , Chen, John J., Sotirchos, Elias S. , Levy, Michael , Flanagan, Eoin P. , Syc‐Mazurek, Stephanie B. , Cacciaguerra, Laura , Rezende, Nathane Braga da Silva, Wingerchuk, Dean M.

Mayo Clinic

JAMA Neurology | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaneurol.2026.2220 | PMID 42440328 Get It

Importance Myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) lacks proven relapse-preventive therapies. While clinical trials are ongoing, safety data may be limited and approved drugs are costly. Studies of interleukin 6 receptor blocker (IL-6RB) in MOGAD are limited by small numbers and no comparative studies, contributing to low use. Objective To evaluate the impact of IL-6RB therapy on relapse rates in MOGAD and compare relapse frequency with intravenous immunoglobulin (IVIG). Design, Setting, and Participants This international, multicenter, retrospective cohort study (January 1, 2015, through December 31, 2025) included a historical IVIG-treated cohort of varying doses. The study took place across sites in North and South America (US, Canada, Mexico, Argentina, Brazil, Chile, Colombia, and Peru). Patients with MOGAD (n = 116, no excluded patients) who received at least 1 dose of an IL-6RB were included. These data were analyzed in January 2026. Exposures Tocilizumab or satralizumab. Main Outcomes and Measures Annualized relapse rate (ARR) during IL-6RB therapy, time to next relapse after treatment initiation, and adverse events. Outcomes were compared with the IVIG cohort using inverse probability of treatment weighting (IPTW) adjusted for age, sex, prior ARR, and concomitant therapies. Results A total of 116 patients with MOGAD (89% relapsing) receiving IL-6RB (tocilizumab, 104 [90%] and satralizumab, 12 [10%]) were included; overall, 60.3% were female, 39.7% were male, and 18% were younger than 18 years. The median (IQR) IL-6RB treatment follow-up was 1.4 (0.7-2.5) years and 23 relapses occurred during 241.8 person-years of IL-6RB therapy. The ARR decreased from 0.64 (95% CI, 0.58-0.70) for relapsing MOGAD before IL-6RB to 0.09 (95% CI, 0.06-0.14) during IL-6RB treatment (incidence rate ratio, 0.08; 95% CI, 0.04-0.16). Adverse events occurred in 58 patients (50%), most commonly mild infections, although 10 (9%) had severe infections. In the IVIG cohort (n = 59), 30 relapses occurred over 133.8 person-years (ARR, 0.22; 95% CI, 0.15-0.32). After IPTW, IL-6RB was associated with a lower hazard ratio (HR) than the group who underwent IVIG therapy less than 1 g/kg every 4 weeks (HR, 4.5; 95% CI, 2.0-9.8), with no significant difference vs the group who underwent IVIG 1 g/kg or more every 4 weeks (HR, 2.0; 95% CI, 0.8-4.5). Conclusions and Relevance In this multicenter observational cohort, IL-6RB use in MOGAD was associated with low relapse rates and a favorable safety profile, though severe infections occurred occasionally. Relapse rates were lower than the group who underwent IVIG less than 1 g/kg every 4 weeks but not significantly different from the group who underwent IVIG 1 g/kg or more every 4 weeks. This supports IL-6RB as a potential relapse-prevention therapy in MOGAD; the wide availability and relative affordability of tocilizumab may enable broad global use.
Sex- and experience-dependent regulation of synaptic protein turnover
Zhang, Shiyu , Pandey, Akhilesh , Bygrave, Alexei M. , Huganir, Richard L. , Pandey, Akhilesh , Bygrave, Alexei M , Huganir, Richard L , Heo, Seok , Mun, Dong‐Gi

Mayo Clinic

Proceedings of the National Academy of Sciences | July 7, 2026 | Volume: 123 | Issue: 28 | Pages: No page available

10.1073/pnas.2602111123 | PMID 42412931 Get It

Synaptic transmission can be tuned through plasticity mechanisms that regulate synaptic strength, structure, and number. In vivo measurements demonstrate remarkable spine dynamics, with subsets of synapses persisting for months. This correlates with the longevity of certain memories, which can persist for an organism’s lifetime. The molecular basis supporting the long-term stability of specific synapses and the long-term durability of memories remains unknown. At the protein level, most proteins persist for a relatively short amount of time before they are degraded and replaced with new molecules. However, recent work has identified a population of proteins, including those present at the synapse, that are exceptionally long-lived. It has been speculated that long-lived proteins (LLPs) could contribute to long-term synapse stability, function, and memory. Here, we used stable isotope labeling in mammals to first identify LLPs in the post synaptic density (PSD) of the hippocampus and subsequently determine if protein turnover rates varied by sex or following learning. We identified synaptic LLPs and found that both sex and experience can regulate synaptic protein turnover rates. We identified sex-dependent changes in protein turnover rates in autism spectrum disorder risk genes, including increased stability of Gabrg2, a GABA-A receptor subunit, in male mice. Furthermore, we observed stabilization of a subset of PSD proteins, such as Shank3, following contextual fear conditioning. We propose that sex- and experience-dependent changes in protein turnover rates could help explain sex-differences in psychiatric risk and aid our understanding of the molecular mechanisms that support learning and memory.
Laparoscopic versus open surgery for rectal cancer: individual patient data meta-analysis of the ALaCaRT and Z6051 randomized trials
Stevenson, Andrew R L, Solomon, Michael J. , Murray, James, Wilson, Kate, Gebski, Val , Fleshman, James, Shi, Qian , Read, Thomas E. , Simes, John, Brown, Kilian G M , Solomon, Michael J , Gebski, Val , Shi, Qian , Brown, Kilian G. M. , Stevenson, Andrew R. L. , Simes, John

Mayo Clinic

BJS Open | July 5, 2026 | Volume: 10 | Issue: 4 | Pages: No page available

10.1093/bjsopen/zrag119 | PMID 42565372 Get It

Abstract Background The multicentre ALaCaRT and ACOSOG Z6051 randomized trials were unable to demonstrate non-inferiority of laparoscopic versus open surgery for rectal cancer with respect to a composite pathology metric indicating successful resection. Neither trial was individually powered to detect differences in long-term recurrence or survival. This planned meta-analysis determined long-term oncological outcomes of laparoscopic versus open proctectomy for rectal adenocarcinoma. Methods This prospective meta-analysis included individual patient data from patients with cT1–3 N0–2 M0 rectal adenocarcinoma enrolled in the ALaCaRT and ACOSOG Z6051 trials. Pathologically successful resection was defined as complete or near-complete total mesorectal excision, a clear circumferential resection margin (CRM; > 1 mm), and a clear distal resection margin (> 1 mm). The non-inferiority margin for disease-free survival (DFS) was an absolute difference of 5% at least 3 years after surgery. Results The combined data set included 935 patients (65.6% men, mean age 60.7 years, mean body mass index 26.7 kg/m2) randomized to open (457 patients) or laparoscopic (478 patients) proctectomy. Pathologically successful resection was lower in the laparoscopic than open group (85.1% versus 89.9%, respectively; pooled estimate 4.6% difference; 95% confidence interval (c.i.) −8.6% to −0.5%). The median follow-up was 60.2 (interquartile range 49.9–61.1) months. Three-year DFS was 75.2% (95% c.i. 71.1% to 79.2%) and 76.5% (95% c.i. 72.5% to 80.6%) for the laparoscopic and open groups, respectively (pooled estimate difference −1.5%; 95% c.i. −7.2% to 4.2%). Non-inferiority of laparoscopic surgery was not demonstrated because the lower one-sided 95% c.i. (−6.3% to 100%) crossed −5%. Three-year locoregional recurrence was higher in laparoscopic than open group (5.4% (95% c.i. 3.3% to 7.5%) versus 2.0% (95% c.i. 0.7% to 3.4%), respectively; pooled estimate 3.1% difference (95% c.i. 0.6% to 5.6%)). A clear CRM was the most significant and only pathological predictor of both DFS (P < 0.0001) and overall survival (P < 0.0001). Conclusion Laparoscopic proctectomy led to a lower rate of pathologically successful resection and a higher rate of locoregional recurrence at 3 years. The possibility of subsequent poorer DFS or overall survival rate requires further evaluation, because this analysis was not specifically powered for these endpoints.
Clinical Practice of Indocyanine Green Fluorescence Imaging in Robotic Liver Surgery – A Global Expert Survey
Aegerter, N L E, Kuemmerli, C, Billeter, A T, Berchtold, C, Nickel, F, Guidetti, C, Wakabayashi, T, Sucandy, I, Goh, B K, D’hondt, M, Marques, H Pinto, Eden, J, Dutkowski, P, Hawksworth, J, Starlinger, P, Müller, B P, Müller, P C, Aegerter, Noa L E , Kuemmerli, Christoph , Billeter, Adrian T. , Berchtold, Caroline , Nickel, Felix , Guidetti, Cristiano , Sucandy, Iswanto , Goh, Brian K P , D’Hondt, Mathieu , Eden, Janina , Dutkowski, Philipp , Hawksworth, Jason Solomon , Müller, P C

Mayo Clinic

British Journal of Surgery | June 3, 2026 | Volume: 113 | Issue: Supplement_5 | Pages: No page available

10.1093/bjs/znag055.029 Get It

Abstract Background Indocyanine green (ICG) fluorescence imaging is increasingly incorporated into robotic liver resections (RLR), yet clinical practice regarding timing, dosage, and staining techniques is divergent. Aims This international expert survey aimed to characterize current practices for ICG in RLR. Methods Experts in RLR were invited to participate based on surgical volume (experience of 50 RLR and 30 annual RLR). A 74-item questionnaire was developed following a literature search and reviewed by a steering committee. The survey addressed indications, timing, dosage, imaging technology, benefits, limitations, training, and future directions of ICG use. Responses collected between September and October 2025 were analyzed. Results Seventy experts from 19 countries completed the survey, corresponding to an 88% response rate. Centers performed a median of 180 annual liver resections, including 55 RLR. Most experts used ICG (96%) during RLR. Anatomical demarcation (91%), tumor localization (60%), and biliary anatomy assessment (60%) were the most frequent indications. 60% of experts use preoperative ICG, while intraoperative ICG is mainly administered for demarcation (67%) and biliary tract visualization (40%). Considerable heterogeneity exists in dosage, timing, and staining techniques, particularly in cirrhotic livers and for tumor localization. Only half of the experts had standard operating procedures, whereas 64% expressed the need for a higher degree of standardization. Reported benefits of ICG use included improved anatomical orientation, margin assessment, lesion detection, and support during complex resections. Perceived limitations included background fluorescence, tissue penetration and variable staining in diseased parenchyma. 80% anticipated improved outcomes with combined ICG and three-dimensional image-guidance. Conclusion ICG fluorescence is widely used in RLR and is an important cornerstone for precision-guided robotic liver surgery. Standardized clinical practice guidelines, structured training, and technological improvements in imaging and navigation systems are claimed to optimize its clinical use.
Mast cell score associates with wide-spread mast cell symptoms and comorbidities in patients with hEDS and HSD
Wilson, Frances C., Zangerle, Derek J. , Rozen, Lincoln E. , Fliess, Jessica J. , Darakjian, Ashley A. , Sacco, Keith , Hamilton, Charwan , Strandes, Max W , Puls, Alayna M , Hartmoyer, Cameron J. , Reyes, Sophia N. Witola , Menton, Stacey M. , Dudenkov, Daniel V. , Gonzalez-Estrada, A, Solomon, Sarah C., Stephens, Ina, Wang, Benjamin W.E., Botella, R, Zeman, Ashley M., Gajarawala, Shilpa , Wilson, Frances C , Sacco, Keith A , Witola Reyes, Sophia N , Gonzalez-Estrada, Alexei , Atwal, Paldeep S , Shufelt, Chrisandra L , Zeman, Ashley M , Knight, Dacre R T , Gajarawala, Shilpa , Bruno, Katelyn A , Fairweather, DeLisa , Gonzalez‐Estrada, Alexei , Solomon, Sarah Cohen, Shufelt, Chrisandra , Bruno, Katelyn A. , Fairweather, DeLisa

Mayo Clinic

No container title available | June 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.31.26354552 | PMID 42282176 Get It

Abstract Background Wide-spread mast cell (MC)-associated symptoms and MC activation syndrome (MCAS) are often reported in patients with hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD). The goal of this study was to develop a novel MC score based on 11 self-reported MC-related conditions with clinical and research utility to better understand MC symptoms in hEDS and HSD patients. Methods From November 1, 2019, to June 13, 2025, patients ( n =2,141) filled out an Intake Questionnaire at the Mayo Clinic Florida EDS Clinic that included 11 self-reported questions related to categories of MC-related conditions for a MC score ranging from 0/11 to 11/11. Based on the MC score distribution in hEDS and HSD patients, a MC score of 0-1 was considered a low MC score and ≥5 was considered a high MC score. Symptoms/comorbidities were compared between patients with high vs. low MC scores. Results From the 2,141 hEDS/HSD patients, 535 (25.0%) had a MC score ≥5 (Hi MC). MCAS-specific symptoms such as nausea and vomiting were reported more often in hEDS/HSD patients with a high vs. low MC score ( p <0.0001). Random clinical blood tryptase and urinary MC markers were not elevated in patients with high MC scores ( n =50/group), although high MC scores were found to significantly reduce urinary creatinine levels indicating that the protein used to normalize data was affected by MC activity. In contrast, random blood IgE, tryptase and major basic protein (MBP) by ELISA were increased in patients with high MC scores (e.g., IgE hEDS p =0.0004, HSD p =0.003). Of note, the percentage of patients reporting abuse or post-traumatic stress disorder was nearly doubled in patients with high vs. low MC scores (Abuse and PTSD: hEDS p < 0.0001; HSD p < 0.0001). Overall, 109/135 (80.7%) in hEDS and 129/135 (95.6%) in HSD reported more symptoms/comorbidities if they had a high MC score. Conclusions We found that hEDS/HSD patients with high MC scores self-reported more widespread symptoms/comorbidities and higher MC-related blood markers than patients with low MC scores indicating the utility of this tool to evaluate the level of widespread MC activity in hEDS, HSD and other patients.
PIEZO1-mediated mechanosensation links aging to bladder dysfunction
Hamed, Yasmeen M F , Joshi, Vikram , Wilhelm, Kevin , Romero, Luis O. , Solomon, Olivia D , Kwok, Tammy B , Gonzalez, Eskarleth D Lopez , Ridlon, Monica , Pendyala, Shriya , Calhoun, Catherine M , Martinez, Alexa , Asmussen, Jennifer , Vásquez, Valeria , Lichtarge, Olivier , Marshall, Kara L. , Lopez Gonzalez, Eskarleth D , Ridlon, Monica , Martinez, Alexa E , Asmussen, Jennifer K , Keil Stietz, Kimberly P , Vezina, Chad M , Vásquez, Valeria , Lichtarge, Olivier , Beyder, Arthur , Marshall, Kara L , Joshi, Vikram , Wilhelm, Kevin O. , Vezina, Chad M. , Beyder, Arthur

Mayo Clinic

No container title available | May 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.24.726025 | PMID 42244605 Get It

SUMMARY Aging is accompanied by profound changes in bladder function, leading to increased urinary frequency and incontinence that impair quality of life in humans and are recapitulated in mouse models. Bladder filling and emptying rely on precise mechanosensory feedback, yet how aging alters this sensory control remains unclear. PIEZO ion channels convert mechanical forces into cellular signals essential for bladder fullness sensation. Using inducible smooth-muscle specific Piezo1 deletion, we find that loss of Piezo1 attenuates aging-related bladder dysfunction. Dietary enrichment with margaric acid, a membrane-active fatty acid previously shown to inhibit PIEZO channels, reduced urinary dysfunction in aged mice. In humans, genotype–phenotype analyses reveal an association between a PIEZO1 gain-of-function variant and early-onset neuromuscular bladder dysfunction. Together, these findings define a smooth-muscle, PIEZO1-mediated mechanosensory basis for aging-related bladder dysfunction and introduce a non-invasive strategy for targeting PIEZO channels in vivo .
B45-11 Baseline Fatigue and Associations With Dyspnea, Exacerbations, and Hospitalizations in Patients With Bronchiectasis
Yohannes, A M, Brunton, A E, Choate, R, Ignatius, E, Aksamit, T R, Maselli, D J, Swenson, C, Geyer, A, Richards, C J, Winthrop, K L, Solomon, G M, YOHANNES, ABEBAW M, Brunton, Amanda E. , Ignatius, Elisa H. , Aksamit, T.R., Geyer, A, Richards, C. , Winthrop, K.L., Solomon, George M

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.1844 Get It

Abstract Introduction Bronchiectasis is a chronic respiratory disease that increases fatigue, disability, and impairs quality of life. However, the impact of fatigue on patients with bronchiectasis, even in short-term follow-up, has not been sufficiently examined. We explored the association between fatigue and clinical outcomes among patients with bronchiectasis. Methods Adult bronchiectasis patients enrolled in the US Bronchiectasis and Nontuberculous Mycobacteria Research Registry were retrospectively analyzed. Patients with at least one annual follow-up visit in the 3-5 years post baseline and with fatigue data at both baseline and follow-up were included. Patients were grouped as experiencing fatigue versus not experiencing fatigue in the 2-years prior to baseline as reported at their baseline visit. We explored the relationship between baseline fatigue with patient demographics, co-existing conditions, components of the modified bronchiectasis severity index at baseline and follow-up. Wilcoxon, chi-square, and Fisher’s exact tests were used to assess the differences in continuous variables and associations between categorical variables, respectively. Stepwise multivariable logistic regression models explored the relationship of baseline fatigue with exacerbations and hospitalizations at follow-up. Model selection predictors were evaluated based on clinical relevance or p &lt; 0.05 in univariable analyses. Results 1265 adults with bronchiectasis met the inclusion criteria. 563(45%) reported experiencing fatigue and 702 (55%) did not. The median age (interquartile range) was 70(62-78) years and patients were predominantly female (n = 1042, 83%). At baseline, patients experiencing fatigue had a higher proportion of co-existing diagnoses such as gastroesophageal reflux disease, chronic obstructive pulmonary disease, and rheumatologic disease, compared to those without fatigue (all p &lt; 0.05). Furthermore, patients with fatigue had a higher prevalence of pulmonary-related hospitalizations (p &lt; 0.001) at baseline and follow-up. Pseudomonas aeruginosa colonization and elevated dyspnea (modified Medical Research Council [mMRC] grade≥1) were more prevalent among those experiencing baseline fatigue compared to those without (all, p &lt; 0.05). History of prior exacerbations (Odds Ratio [OR]:1.67, 95% CI:1.17-2.41) and baseline Pseudomonas aeruginosa colonization (OR:1.22, 95% CI:1.01-1.47) were significantly associated with increased odds of exacerbations at follow-up. In multivariable stepwise logistic regression, there was an increased odds of at least 1-hospitalization at follow-up among males (OR:2.23, 95% CI 1.12-4.42), patients with decreased Body Mass Index (OR:0.93, 95% CI: 0.87-1.0), and among patients with elevated dyspnea (mMRC grade ≥1) at baseline (OR:2.22, 95% CI: 1.16-4.24),[Table 1]. Conclusions Fatigue in bronchiectasis patients is associated with a more severe disease and greater healthcare utilization, although it may not independently predict future exacerbations or hospitalizations when accounting for other factors. This abstract is funded by: Bronchiectasis and NTM Association